MX2022008148A - Inhibidores de btk. - Google Patents
Inhibidores de btk.Info
- Publication number
- MX2022008148A MX2022008148A MX2022008148A MX2022008148A MX2022008148A MX 2022008148 A MX2022008148 A MX 2022008148A MX 2022008148 A MX2022008148 A MX 2022008148A MX 2022008148 A MX2022008148 A MX 2022008148A MX 2022008148 A MX2022008148 A MX 2022008148A
- Authority
- MX
- Mexico
- Prior art keywords
- manufacture
- btk inhibitors
- compounds
- medicaments
- possess
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Abstract
(ver Fórmula) La invención se refiere a compuestos químicos, o sales farmacéuticamente aceptables de estos, de la fórmula (I) que poseen actividad inhibitoria de BTK y son en consecuencia útiles en terapia y en métodos de tratamiento del cuerpo humano o animal. La invención también se refiere a procesos para fabricar dichos compuestos químicos, a composiciones farmacéuticas que los contienen, y a su uso en la fabricación de medicamentos para uso en un efecto terapéutico en un animal endotermo, tal como el ser humano.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020070034 | 2020-01-02 | ||
CN2020134601 | 2020-12-08 | ||
PCT/CN2020/140517 WO2021136219A1 (en) | 2020-01-02 | 2020-12-29 | Btk inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022008148A true MX2022008148A (es) | 2022-07-21 |
Family
ID=76685855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022008148A MX2022008148A (es) | 2020-01-02 | 2020-12-29 | Inhibidores de btk. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230122807A1 (es) |
EP (1) | EP4087845A4 (es) |
JP (1) | JP2023510212A (es) |
KR (1) | KR20220123446A (es) |
CN (1) | CN114945574A (es) |
AU (1) | AU2020419422A1 (es) |
BR (1) | BR112022013227A2 (es) |
CA (1) | CA3163365A1 (es) |
MX (1) | MX2022008148A (es) |
TW (1) | TW202136267A (es) |
WO (1) | WO2021136219A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113943294A (zh) * | 2020-07-15 | 2022-01-18 | 成都海博为药业有限公司 | 一种作为btk抑制剂的化合物及其制备方法与用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011520970A (ja) * | 2008-05-19 | 2011-07-21 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換されたイミダゾピラジン類およびイミダゾトリアジン類 |
US9376438B2 (en) * | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
CA2833867A1 (en) * | 2013-11-21 | 2015-05-21 | Pharmascience Inc. | Protein kinase inhibitors |
TW201618783A (zh) * | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
WO2016106652A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Biarylether imidazopyrazine btk inhibitors |
US20180305350A1 (en) * | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
JP6715357B2 (ja) * | 2016-06-30 | 2020-07-01 | 杭州三因泰医薬科技有限公司Hangzhou Sanyintai Pharmaceutical Technology Co., Ltd. | イミダゾピリジンアミンフェニル誘導体およびその使用 |
JP2022517280A (ja) * | 2019-01-18 | 2022-03-07 | シービン リィアォ | ブルトン型チロシンキナーゼ阻害剤 |
CN111454268B (zh) * | 2019-01-18 | 2023-09-08 | 明慧医药(上海)有限公司 | 作为布鲁顿酪氨酸激酶抑制剂的环状分子 |
CN113943294A (zh) * | 2020-07-15 | 2022-01-18 | 成都海博为药业有限公司 | 一种作为btk抑制剂的化合物及其制备方法与用途 |
-
2020
- 2020-12-29 AU AU2020419422A patent/AU2020419422A1/en active Pending
- 2020-12-29 BR BR112022013227A patent/BR112022013227A2/pt unknown
- 2020-12-29 JP JP2022540849A patent/JP2023510212A/ja active Pending
- 2020-12-29 CA CA3163365A patent/CA3163365A1/en active Pending
- 2020-12-29 TW TW109146658A patent/TW202136267A/zh unknown
- 2020-12-29 US US17/790,721 patent/US20230122807A1/en active Pending
- 2020-12-29 MX MX2022008148A patent/MX2022008148A/es unknown
- 2020-12-29 CN CN202080091669.XA patent/CN114945574A/zh active Pending
- 2020-12-29 EP EP20910897.6A patent/EP4087845A4/en active Pending
- 2020-12-29 KR KR1020227026622A patent/KR20220123446A/ko unknown
- 2020-12-29 WO PCT/CN2020/140517 patent/WO2021136219A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3163365A1 (en) | 2021-07-08 |
WO2021136219A1 (en) | 2021-07-08 |
CN114945574A (zh) | 2022-08-26 |
TW202136267A (zh) | 2021-10-01 |
AU2020419422A1 (en) | 2022-06-02 |
US20230122807A1 (en) | 2023-04-20 |
BR112022013227A2 (pt) | 2022-09-06 |
EP4087845A4 (en) | 2024-01-24 |
JP2023510212A (ja) | 2023-03-13 |
EP4087845A1 (en) | 2022-11-16 |
KR20220123446A (ko) | 2022-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200634003A (en) | Chemical compounds | |
TW200616974A (en) | Chemical compounds | |
TW200635899A (en) | Chemical compounds | |
TW200621259A (en) | Chemical compounds | |
MX2007008924A (es) | Compuestos quimicos. | |
TW200621730A (en) | Chemical compounds | |
MX2009004908A (es) | Compuestos quimicos. | |
PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
TW200736234A (en) | Chemical compounds | |
MX2023003564A (es) | Compuestos y su uso en el tratamiento del cancer. | |
ATE369353T1 (de) | Medizinisch verwendbare arylethanolamin verbindungen | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
BRPI0512075A (pt) | composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença | |
SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
BRPI0518126A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença ou condição | |
SG148177A1 (en) | Novel cis-imidazolines | |
MX2020010322A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). | |
MX2023007853A (es) | Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo. | |
MX2009004906A (es) | Sulfonamidas heterociclicas que tienen actividad antagonistica del edg-1. | |
MX2022005985A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
CR20210630A (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
MXPA05012675A (es) | Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa. | |
MX2009007889A (es) | Derivados de 3-cinnolincarboxamida y su uso para el tratamiento del cancer. | |
MX2022012351A (es) | Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres. |